文献速递心血管胸部技术与安全CT

为冠状动脉计算机断层扫描血管造影显示动脉粥样硬化斑块的患者指导自动化实施策略:人工智能-DECIDE 研究的原理与设计

Guiding Automated Implementation Strategies for Patients With Atherosclerotic Plaque on Coronary Computed Tomographic Angiography: Rationale and Design of the Artificial Intelligence-DECIDE Study.
PubMed 文献 · JACC Cardiovasc Imaging · 2025-07-16

DECIDE 研究计划纳入约 20,000 例因疑似或已知冠状动脉疾病接受诊断检查的患者(约 40 个中心),通过自动化电子健康记录提取评估定量冠状动脉斑块测量对预防性和抗缺血治疗及血运重建的影响。研究设置 6 条诊疗路径,在部分亚组中比较即时或延迟 90 天提供人工智能定量斑块测量与仅基于狭窄指导的治疗决策。

要点

  • 研究将比较仅基于冠状动脉狭窄与基于人工智能定量斑块测量指导的治疗决策。
  • 计划纳入约 20,000 例患者,覆盖约 40 个中心,随访 1 年。
  • 评估 6 条诊疗路径,包括无定量斑块、延迟定量斑块、即时定量斑块及负荷试验对照。

核心结论

  • DECIDE 研究将纳入并表征需要启动和强化预防治疗的广泛患者人群,利用高效自动化系统评估定量动脉粥样硬化斑块测量对预防治疗的影响,以帮助指导实施策略、改善接受冠状动脉 CTA 患者的结局。

研究设计与样本

  • 多中心研究,计划纳入约 20,000 例患者(约 40 个中心),因疑似或已知冠状动脉疾病接受诊断检查,通过自动化电子健康记录数据提取收集 1 年随访内的药物治疗变化和冠状动脉血运重建;在部分亚组中,人工智能支持的定量冠状动脉斑块测量(QCPA)即时或延迟 90 天提供。

诊断标准与关键数值

  • 将评估 6 条诊疗路径:1)不提供 QCPA(常规检查);2)提供 QCPA 但延迟,随后纳入修订的最终报告以指导患者管理;3)对未血运重建患者即时提供 QCPA;4)对既往 1 支血管支架置入患者即时提供 QCPA;5)对转诊行冠状动脉 CTA 的无症状患者即时提供 QCPA;6)转诊行负荷试验但无冠状动脉 CTA 的患者(即对照)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Approximately half of the patients with abnormal findings have no minimal changes in clinical management after stress testing.

OBJECTIVES: The primary aim of this study is to assess changes in preventive and anti-ischemic care for stable patients with atherosclerotic plaque on coronary computed tomographic angiography (CTA).

METHODS: Projected enrollment is 20,000 patients (∼40 sites) who underwent diagnostic testing for suspected or known coronary artery disease. Changes in medical therapy (dosing and type) and coronary revascularization will be collected through an automated electronic health record data extraction through 1 year of follow-up. In select subgroups, artificial intelligence-enabled quantitative measures of coronary atherosclerotic plaque (QCPA) will be provided promptly or delayed by 90 days, such that prompt decisions guided by coronary artery disease stenosis alone can be compared with QCPA-guided treatment.

RESULTS: A total of 6 care pathways will be evaluated: 1) no QCPA is provided (usual testing); 2) QCPA is provided but delayed and subsequently incorporated into a revised final report to guide patient management; 3) immediate QCPA is provided in nonrevascularized patients; 4) immediate QCPA is provided to patients with prior stenting in 1 vessel; 5) immediate QCPA is provided to asymptomatic patients referred for coronary CTA; and 6) patients referred to stress testing with no coronary CTA (ie, the comparator).

CONCLUSIONS: The DECIDE (DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD management) study will enroll and characterize a broad spectrum of patients who require initiation and intensification of preventive care. The authors will use efficient and automated systems to evaluate the impact of quantitative atherosclerotic plaque measurement on preventive care that will help guide implementation strategies to improve outcomes for patients undergoing coronary CTA.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Rinehart S, Blankstein R, Januzzi JL, et al. Guiding Automated Implementation Strategies for Patients With Atherosclerotic Plaque on Coronary Computed Tomographic Angiography: Rationale and Design of the Artificial Intelligence-DECIDE Study. JACC Cardiovasc Imaging. 2025. PMID: 40673854. doi:10.1016/j.jcmg.2025.03.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。